Regeneron buying stake in Parabilis as part of multi-target Helicon tie-up: Deals Report

Parabilis’ multi-target deal with Regeneron will fortify the private biotech’s balance sheet with $50 million in upfront cash and a $75 million equity commitment toward its next financing as the partners explore uses of its Helicon platform.

The collaboration will give Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) development and commercialization rights to programs discovered jointly from the platform developed by Parabilis Medicines Inc. Using Helicon, the biotech aims to create orally available, conformationally stabilized peptide therapies that can reach difficult-to-drug targets via protein-protein interactions on surfaces that lack small molecule pockets; Monday’s deal encompasses both standalone Helicons and antibody conjugates...